CRVO Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

2.730

Open

2.700

VWAP

2.37

Vol

1.03M

Mkt Cap

26.76M

Low

2.153

Amount

2.45M

EV/EBITDA(TTM)

--

Total Shares

9.26M

EV

13.83M

EV/OCF(TTM)

--

P/S(TTM)

12.70

CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.

Show More

Events Timeline

(ET)

2026-04-22

09:20:00

CervoMed Study Shows Neflamapimod May Improve Basal Forebrain Function in DLB Patients

2026-03-19 (ET)

2026-03-19

08:00:00

CervoMed Presents New Data on Neflamapimod at AD/PD 2026 Conference

2026-03-17 (ET)

2026-03-17

07:50:00

CervoMed Expects Cash to Fund Operations for Six Months

2026-03-12 (ET)

2026-03-12

07:30:00

CervoMed to Present Neflamapimod Research Progress at AD/PD 2026

2026-03-04 (ET)

2026-03-04

07:40:00

CervoMed Completes Phase 1 Study of Neflamapimod

2026-02-18 (ET)

2026-02-18

06:20:00

CervoMed's Oral Drug Neflamapimod Included in EXPERTS-ALS Platform

News

Newsfilter

11:43 AMNewsfilter

PinnedCervoMed Secures $10.5 Million Financing to Advance Neflamapimod

stocktwits

14:10 PMstocktwits

CervoMed Financing Plan Triggers Stock Price Plunge

seekingalpha

05-18seekingalpha

CervoMed Reports Q1 Financial Results with Increased Losses

Newsfilter

05-18Newsfilter

CervoMed Advances Phase 3 Trial for DLB

Newsfilter

04-22Newsfilter

CervoMed Presents New Therapy for Neurodegenerative Disease

Newsfilter

04-07Newsfilter

CervoMed Updates on Clinical Trial Progress for Neflamapimod

5 Analyst Rating

Wall Street analysts forecast CRVO stock price to rise

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

19.00

Averages

22.75

High

27.00

Current: 0.000

Low

19.00

Averages

22.75

High

27.00

Roth Capital

Buy

downgrade

$11 -> $9

AI Analysis

2026-05-18

Reason

Roth Capital

Price Target

$11 -> $9

AI Analysis

2026-05-18

downgrade

Buy

Reason

Roth Capital lowered the firm's price target on CervoMed to $9 from $11 and keeps a Buy rating on the shares. The firm notes that Neflamapimod's ability to improve CDR-SB with an acceptable safety profile continues to support is by recommendation. Roth adds that it expects Phase 3 study to begin in the second half of 2026, given an alignment with regulators has already been achieved. The firm states, however, that the key sticking point for stock appreciation is the ongoing financing overhang.

Chardan

Buy

upgrade

$15 -> $21

2026-03-17

Reason

Chardan

Price Target

$15 -> $21

2026-03-17

upgrade

Buy

Reason

Chardan raised the firm's price target on CervoMed to $21 from $15 and keeps a Buy rating on the shares. The neflamapimod program is fully back on track following alignment reached with the FDA in November 2025 for a Phase 3 registrational study in dementia with Lewy bodies, the analyst tells investors in a research note. With strong efficacy data with the new neflamapimod product batch in the completed Phase 2 study and with alignment on patient selection, a new drug formulation reaching desired drug plasma levels, and a new higher dose in the planned Phase 3 study, the firm is increasingly confident in the successful outcome of the DLB program.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CRVO

Unlock Now

Valuation Metrics

The current forward P/E ratio for CervoMed Inc (CRVO.O) is 0.00, compared to its 5-year average forward P/E of -5.71. For a more detailed relative valuation and DCF analysis to assess CervoMed Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-5.71

Current PE

0.00

Overvalued PE

-2.21

Undervalued PE

-9.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-3.83

Current EV/EBITDA

-1.81

Overvalued EV/EBITDA

0.38

Undervalued EV/EBITDA

-8.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

25.56

Current PS

38.11

Overvalued PS

47.66

Undervalued PS

3.47

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

can you limit the choices to only 5 stocks

Intellectia · 724 candidates

Price: <= $10.00Pe Ttm: <= 15Target Price Upside Potential: MoreAbovePrice

Ticker

Name

Market Cap$

Flux Power Holdings Inc

31.80M

Organogenesis Holdings Inc

487.34M

Sangamo Therapeutics Inc

127.97M

Aquestive Therapeutics Inc

409.93M

Traws Pharma Inc

19.42M

BTCS Inc

126.36M

Whales Holding CRVO

Trading Trends

People Also Watch

Frequently Asked Questions

What is CervoMed Inc (CRVO) stock price today?

The current price of CRVO is 2.23 USD — it has decreased -22.84

What is CervoMed Inc (CRVO)'s business?

CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.

What is the price predicton of CRVO Stock?

Wall Street analysts forecast CRVO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRVO is22.75 USD with a low forecast of 19.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is CervoMed Inc (CRVO)'s revenue for the last quarter?

CervoMed Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00

What is CervoMed Inc (CRVO)'s earnings per share (EPS) for the last quarter?

CervoMed Inc. EPS for the last quarter amounts to -0.86 USD, increased 53.57

How many employees does CervoMed Inc (CRVO). have?

CervoMed Inc (CRVO) has 15 emplpoyees as of June 10 2026.

What is CervoMed Inc (CRVO) market cap?

Today CRVO has the market capitalization of 26.76M USD.